Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.59 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.59 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.55 |
| ▸ | HTT | P42858 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.54 |
| ▸ | F2RL1 | P55085 | 1/20 | 0.53 |
| ▸ | NPC1 | O15118 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | IDO1 | P14902 | 2/20 | 0.52 |
| ▸ | AGXT | P21549 | 2/20 | 0.52 |
| ▸ | MMP1 | P03956 | 1/20 | 0.51 |
| ▸ | MMP9 | P14780 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | LDHA | P00338 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30984667 | 0.95 | ALDH1A1 (0.59) | ALDH1A1L3MBTL1MAPK1KMT2AHTT | |
| SCHEMBL3727515 | 0.93 | FFAR1 (0.60) | ALDH1A1L3MBTL1MAPK1KMT2AHTT | |
| SCHEMBL18782519 | 0.93 | ALDH1A1 (0.54) | ALDH1A1L3MBTL1MAPK1KMT2AHTT | |
| SCHEMBL18381104 | 0.93 | ALDH1A1 (0.54) | ALDH1A1L3MBTL1MAPK1KMT2AHTT | |
| SCHEMBL24387813 | 0.91 | ALDH1A1 (0.60) | ALDH1A1L3MBTL1MAPK1KMT2AHTT | |
| SCHEMBL18381100 | 0.91 | ALDH1A1 (0.53) | ALDH1A1L3MBTL1MAPK1KMT2AHTT | |
| SCHEMBL357272 | 0.91 | ALDH1A1 (0.53) | ALDH1A1L3MBTL1MAPK1KMT2AHTT | |
| SCHEMBL28812413 | 0.89 | ALDH1A1 (0.51) | ALDH1A1L3MBTL1MAPK1KMT2AHTT | |
| SCHEMBL27790577 | 0.89 | ALDH1A1 (0.51) | ALDH1A1L3MBTL1MAPK1KMT2AHTT | |
| SCHEMBL10399769 | 0.89 | ALDH1A1 (0.66) | ALDH1A1L3MBTL1MAPK1KMT2AHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118271170-A | 1, 2-Dioleoyl-SN-glycerinum-3-succinic acid and preparation method thereof | 苏州昊帆生物股份有限公司 | 2024-07-02 | — | — | CN | claimed |
| CN-118271170-A | 1, 2-Dioleoyl-SN-glycerinum-3-succinic acid and preparation method thereof | 苏州昊帆生物股份有限公司 | 2024-07-02 | — | — | CN | disclosed |
| CN-118271170-A | 1, 2-Dioleoyl-SN-glycerinum-3-succinic acid and preparation method thereof | 苏州昊帆生物股份有限公司 | 2024-07-02 | — | — | CN | disclosed |
| US-7825238-B2 | Antiviral methods employing double esters of 2′, 3′-dideoxy-3′-fluoroguanosine | MEDIVIR AB (SE) | 2010-11-02 | — | — | US | disclosed |
| CN-100460417-C | Nucleosides analogues, such as antivirals including inhibitors of retroviral reverse transcriptase and the DNA polymerase | MEDIVIR AB HUDDINGE (SE) | 2009-02-11 | — | — | CN | disclosed |
| CN-1872869-A | Nucleosides analogues, such as antivirals including inhibitors of retroviral reverse transcriptase and the DNA polymerase | MEDIVIR AB HUDDINGE (SE) | 2006-12-06 | — | — | CN | disclosed |
| CN-1286845-C | Nucleoside analogs as antiviral agents for retroviral reverse transcriptase and DNA polymerase inhibitors | MEDIVIR AB (SE) | 2006-11-29 | — | — | CN | disclosed |
| US-7071173-B2 | Antiviral methods employing double esters of 2′, 3′-dideoxy-3′-fluoroguanosine | MEDIVIR AB (SE) | 2006-07-04 | — | — | US | disclosed |
| US-20060122383-A1 | Antiviral methods employing double esters of 2', 3'-dideoxy-3'-fluoroguanosine | MEDIVIR AB (SE) | 2006-06-08 | — | — | US | disclosed |
| US-20060058259-A1 | ANTIVIRAL METHODS EMPLOYING DOUBLE ESTERS OF 2', 3'-DIDEOXY-3'-FLUOROGUANOSINE | MEDIVIR AB (SE) | 2006-03-16 | — | — | US | disclosed |
| US-20020128301-A1 | Non-nucleoside reverse transcriptase inhibitors | AB, Medivir (SE) | 2002-09-12 | — | — | US | disclosed |
| EP-1150956-A1 | NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | MEDIVIR AB (SE) | 2001-11-07 | — | — | EP | disclosed |
| EP-1123935-A2 | 3'-Fluorinated guanosine derivatives for the treatment or prophylaxis of HBV or retroviral infections | MEDIVIR AB (SE) | 2001-08-16 | — | — | EP | disclosed |
| EP-0988304-B1 | NUCLEOSIDES ANALOGUES, SUCH AS ANTIVIRALS INCLUDING INHIBITORS OF RETROVIRAL REVERSE TRANSCRIPTASE AND THE DNA POLYMERASE OF HEPATITIS B VIRUS (HBV) | MEDIVIR AB (SE) | 2001-05-02 | — | — | EP | disclosed |
| CN-1275983-A | Nucleoside analogues, these compounds as antiviral agents comprising inhibitors of the reverse transcriptase and DNA polymerase of retroviruses of Hepatitis B Virus (HBV) | MEDIVIR AB (SE) | 2000-12-06 | — | — | CN | disclosed |
| EP-1054891-A1 | PRODRUGS | MEDIVIR AB (SE) | 2000-11-29 | — | — | EP | disclosed |
| WO-2000047561-A1 | NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | MEDIVIR AB (SE) | 2000-08-17 | — | — | WO | disclosed |
| EP-0988304-A1 | NUCLEOSIDES ANALOGUES, SUCH AS ANTIVIRALS INCLUDING INHIBITORS OF RETROVIRAL REVERSE TRANSCRIPTASE AND THE DNA POLYMERASE OF HEPATITIS B VIRUS (HBV) | MEDIVIR AB (SE) | 2000-03-29 | — | — | EP | disclosed |
| WO-1999041275-A1 | PRODRUGS | MEDIVIR AB (SE) | 1999-08-19 | — | — | WO | disclosed |
| WO-1999009031-A1 | NUCLEOSIDES ANALOGUES, SUCH AS ANTIVIRALS INCLUDING INHIBITORS OF RETROVIRAL REVERSE TRANSCRIPTASE AND THE DNA POLYMERASE OF HEPATITIS B VIRUS (HBV) | MEDIVIR AB (SE) | 1999-02-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060058259-A1 | ANTIVIRAL METHODS EMPLOYING DOUBLE ESTERS OF 2', 3'-DIDEOXY-3'-FLUOROGUANOSINE | UNG, HAVCR2, EIF2AK2 | ALDH1A1 1605/4885L3MBTL1 3294/4885MAPK1 3742/4885 |
| US-20060122383-A1 | Antiviral methods employing double esters of 2', 3'-dideoxy-3'-fluoroguanosine | UNG, HAVCR2, EIF2AK2 | ALDH1A1 1605/4885L3MBTL1 3294/4885MAPK1 3742/4885 |
| US-20020128301-A1 | Non-nucleoside reverse transcriptase inhibitors | SUB1, CBR1, GAR1 | ALDH1A1 1104/4885L3MBTL1 521/4885MAPK1 2356/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.